Logo BaseClick

Baseclick GmbH files a new patent

in the field of mRNA modification

In the last 20 years, a rapidly expanding research area of RNA-based therapeutic innovations has emerged.  This novel established therapeutic treatment take aim of difficult-to-treat diseases and untreatable targets. Therefore, research & development of renowned pharmaceutical companies and specialists focuses on the use of messenger RNA (mRNA). With features such as high selectivity, general biodegradability, rational design and the ability to adapt to disease changes mRNA gets in the focus of interest as a new drug candidate.
So far, however, the challenge for scientists are the bioavailability, the release and efficacy (mainly due to their chemical properties) of the mRNA drug candidates.
Therefore, baseclick GmbH has set out to work on solutions. The team is working on multifunctional and flexible modification system using bioconjugation to enable efficient transfection and in vivo translation of labeled mRNA.
The company’s proprietary technology of “click chemistry” allowed already the detection of the complete activity of mRNA during the translation in HeLa cancer cells. In a next step, the company will prove new application approaches in drug development technology. A first cornerstone was laid at the end of 2017 with the submission of the invention EP 2017/17209585 ("Click-modified in vitro transcribed mRNA for gene expression").
"We were very surprised about the efficiency and acceptance of the modified mRNA in our first unoptimized experiments" Dr. Thomas Frischmuth, CEO of baseclick.
In order to make this new and highly potent technology available for research & development, baseclick GmbH has launched a new kit for mRNA modification and tracking. More information can be found here.

News Archive Archive News